Xencor Inc (NASDAQ:XNCR) major shareholder John S. Stafford III purchased 38,300 shares of the stock in a transaction on Friday, March 15th. The shares were bought at an average cost of $29.02 per share, for a total transaction of $1,111,466.00. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Shares of NASDAQ XNCR traded down $0.15 during midday trading on Tuesday, hitting $30.27. 96,145 shares of the company’s stock were exchanged, compared to its average volume of 218,691. Xencor Inc has a 12 month low of $27.57 and a 12 month high of $48.38. The company has a market capitalization of $1.69 billion, a P/E ratio of -23.11 and a beta of 1.40.
Several research analysts have weighed in on XNCR shares. Zacks Investment Research lowered Xencor from a “buy” rating to a “hold” rating in a research report on Tuesday, November 20th. BidaskClub raised Xencor from a “hold” rating to a “buy” rating in a research report on Friday, November 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Xencor in a research report on Friday, November 23rd. Finally, Wedbush boosted their price target on Xencor from $42.00 to $44.00 and gave the stock an “outperform” rating in a research report on Friday, December 7th. Two equities research analysts have rated the stock with a sell rating and nine have assigned a buy rating to the stock. Xencor currently has a consensus rating of “Buy” and an average target price of $40.43.
COPYRIGHT VIOLATION NOTICE: “Xencor Inc (XNCR) Major Shareholder Purchases $1,111,466.00 in Stock” was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.tickerreport.com/banking-finance/4233621/xencor-inc-xncr-major-shareholder-purchases-1111466-00-in-stock.html.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Read More: What are the benefits of momentum investing?
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.